Matt Wall
About Matt Wall
Matt Wall serves as the Director of Regulatory Project Management at Mirum Pharmaceuticals, Inc., where he has worked since 2023. He has extensive experience in regulatory project management, having previously held positions at BioMarin Pharmaceutical Inc. and Takeda Oncology, and has contributed to the development of several notable medical products.
Current Role at Mirum Pharmaceuticals
Matt Wall serves as the Director of Regulatory Project Management at Mirum Pharmaceuticals, Inc. He has held this position since 2023. In this role, he oversees regulatory strategies and project management initiatives, ensuring compliance with industry standards and facilitating the development of pharmaceutical products.
Previous Experience at Mirum Pharmaceuticals
Prior to his current role, Matt Wall worked at Mirum Pharmaceuticals, Inc. as the Associate Director of Regulatory Project Management from 2021 to 2023. During this time, he contributed to regulatory submissions and project oversight, enhancing the company's regulatory framework.
Professional Background in Regulatory Affairs
Matt Wall has extensive experience in regulatory affairs, having worked at BioMarin Pharmaceutical Inc. in various roles from 2017 to 2021. He started as a Regulatory Project Manager I and progressed to Senior Regulatory Project Manager and Head of Cross-Program Collaborations Team. His work involved managing regulatory submissions and cross-functional collaborations.
Educational Qualifications
Matt Wall has a strong educational background, having studied at several prestigious institutions. He earned a Bachelor of Science in Microbiology and Immunology from McGill University. He also completed various certifications, including Negotiation Mastery from Harvard Business School Online and Leadership & Innovation from the Massachusetts Institute of Technology.
Contributions to Pharmaceutical Development
Throughout his career, Matt Wall has contributed to the development of several notable pharmaceutical products. He played a role in the development of Sephure®, Synalax™, and various first-in-class therapies such as ROCTAVIAN™ and PALINZIQ™. His involvement spans multiple therapeutic areas, showcasing his expertise in regulatory project management.